Abstract: The present disclosure relates to delivery systems and methods for increasing the bioavailability and increasing the absorption rate by monolithic enteric capsule administration to humans of active ingredients compared to the bioavailability of active ingredients enterically coated for modified release or gastric protection, particularly acid sensitive active ingredients such as esomeprazole, omeprazole, and other proton pump inhibitors, systems for delivering active pharmaceutical ingredients to humans or animals via monolithic enteric capsules, and improved methods of treating gastrointestinal disorders with such methods and delivery systems.
Abstract: The present disclosure relates to a composition to aid in heavy metal detox. Metallothioneins (MT) are a family of cysteine-rich enzymes in the body that help remove and regulate heavy metals, copper, and other metals. Amino Acids in combination with zinc and/or molybdenum may provide improved production of MT over amino acid or zinc supplements alone. Additionally, Vitamin B6, Molybdenum, and Boron may be included to further enhance the efficacy of the composition.
Abstract: The invention discloses a trace element solution, which comprises at least the following metals: at least 65 mg/ml zinc directly and/or indirectly from mineral EDTA chelate(s) and/or Zn Oxide; at least 10 mg/ml manganese directly and/or indirectly from mineral EDTA chelate(s) and/or Mn carbonate; at least 15 mg/ml copper directly and/or indirectly from mineral EDTA chelate(s) and/or copper sulphate and/or copper oxide and/or carbonate; and at least 5 mg/ml selenium. The trace element solution comprises at least the following: at least 65 mg/ml zinc derived directly and/or indirectly from ZN-EDTA and/or Zn Oxide; at least 10 mg/ml manganese derived directly and/or indirectly from Mn-EDTA and/or Mn carbonate; at least 15 mg/ml copper derived directly and/or indirectly from Cu-EDTA and/or copper oxide and/or copper sulphate and/or copper carbonate; and at least 5 mg/ml selenium derived directly and/or indirectly from Na2SeO4 and/or Na2SeO3.
Abstract: A formulation includes a nanostructured lipid carrier (NLC) matrix and spironolactone as an active ingredient loaded within the NLC matrix, forming a spironolactone-loaded NLC (SP-NLC) gel or lotion.
Abstract: The present invention includes a low dose and sustained release formulation of 2,4-dinitrophenol (DNP). The compositions of the invention are useful for preventing or treating a disease or disorder, such as non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, insulin resistance and/or diabetes, in a subject in need thereof.
Type:
Grant
Filed:
August 29, 2014
Date of Patent:
September 29, 2020
Assignee:
Yale University
Inventors:
Gerald I. Shulman, Rachel Jamison Perry
Abstract: A respirable dry powder including acetylsalicylic acid in particles has a mass median aerodynamic diameter (MMAD) within a range of about 0.5 ?m to about 10 ?m. The respirable dry powder may contain a pharmaceutically acceptable excipient, such as a phospholipid, in an amount ranging from about 0.1% (w/w) to about 10% (w/w) of the particles.
Abstract: A delayed release coating includes a mixture of a first material selected from starch; amylose; amylopectin; chitosan; chondroitin sulfate; cyclodextrin; dextran; pullulan; carrageenan; scleroglucan; chitin; curdulan and levan, and a second material which has a pH threshold at about pH 5 or above. The delayed release coating is used to target release of a drug from a core to the intestine, particularly the colon.
Abstract: The present invention provides methods of treating arthritis. A sustained release composition comprising liposomes and one or more therapeutic agent or a pharmaceutically acceptable salt thereof is administered to a subject in need thereof. The liposomes may be in an aqueous suspension. The sustained release composition can be administered intraarticularly.
Type:
Grant
Filed:
June 12, 2019
Date of Patent:
August 11, 2020
Assignees:
TAIWAN LIPOSOME CO., LTD., TCL BIOPHARMACEUTICALS, INC.
Inventors:
Keelung Hong, Luke S. S. Guo, Yun-Long Tseng, Sheue-Fang Shih, Po-Chun Chang, Chih-Chiang Tsai, Hong-Hui Lin
Abstract: The present invention relates to a topical ophthalmic formulation comprising at least one antagonist of the endothelin receptor, preferably selected from sitaxentan, ambrisentan, atrasentran, bosentan, macitentan and tezosentan, or a mixture thereof, more preferably bosentan. It also relates to the use of a topical ophthalmic formulation comprising at least one antagonist of the endothelin receptor, preferably selected from sitaxentan, ambrisentan, atrasentran, bosentan, macitentan and tezosentan, or a mixture thereof, more preferably bosentan, as active ingredient for preventing and/or treating the retinal neurodegeneration induced by diabetes and/or aging.
Type:
Grant
Filed:
March 22, 2016
Date of Patent:
July 21, 2020
Assignee:
Retinset, S.L.
Inventors:
Vicente Duran Muiños, Marta Guerrero Martínez, Cristina Hernández Pascual, José Bruno Montoro Ronsano, Rafael Simó Canonge, José Maria Suñé Negre, José Ramón Ticó Grau
Abstract: A method of treating a disease state or condition in humans via topical brainstem afferent stimulation therapy via the administration of a cannabinoid drug(s) to the back of the neck of a human patient to provide regional neuro-affective therapy is disclosed. In certain preferred embodiments, the cannabinoid drug(s) are not psychoactive or substantially not psychoactive. In certain embodiments, the cannabinoid drug(s) are incorporated into a pharmaceutically acceptable topical carrier, e.g., a cream. In certain preferred embodiments, the cannabinoid drug(s) comprises cannabidiol.
Abstract: In one embodiment, the present application discloses compositions and methods of solubilizing pterostilbene or resveratrol, or mixture thereof in aqueous media.
Type:
Grant
Filed:
January 10, 2018
Date of Patent:
July 7, 2020
Assignee:
Ironstone Separations, Inc.
Inventors:
James D. McChesney, Igor Nikoulin, Douglas L. Rodenburg
Abstract: A reactive oxygen species savaging emulsion; the emulsion comprising an injectable pharmaceutically acceptable composition and a polymeric poly(propylene sulfide) microsphere for targeted delivery to a site with elevated reactive oxygen species. In embodiments of the present invention, the microsphere is loaded with a biologically active agent.
Type:
Grant
Filed:
November 19, 2015
Date of Patent:
June 30, 2020
Assignee:
Vanderbilt University
Inventors:
Craig L. Duvall, John R. Martin, Kristin P. O'Grady, Christopher E. Nelson
Abstract: The present invention provides a low-toxicity sophorolipid-containing composition. The low-toxicity sophorolipid-containing composition contains at least a coloring component, an acidic sophorolipid, a fatty acid, and a hydroxy fatty acid that are derived from an SL-producing yeast culture. The composition contains the following components in the following proportions, in terms of dry weight, based on the total amount of the acidic sophorolipid, a lactonic sophorolipid, the fatty acid, and the hydroxy fatty acid in the composition taken as 100 mass %: (1) acidic sophorolipid: 94 to 99.99 mass %, (2) lactonic sophorolipid: 0 to 2 mass %, (3) total amount of fatty acid and hydroxy fatty acid: 0.01 to 4 mass %.
Abstract: Provided are methods for treating calcium malabsorption and conditions associated with calcium malabsorption, employing the administration of a composition containing stable amorphous calcium carbonate. Further provided are methods for increasing bone mineral density in a bone metabolism associated disorders, diseases or conditions, employing the administration of said composition in combination with a bone resorption inhibitor.
Type:
Grant
Filed:
July 31, 2018
Date of Patent:
June 23, 2020
Assignee:
AMORPHICAL LTD
Inventors:
Amir Sagi, Assaf Shechter, Galit Shaltiel-Gold, Michal Daniely, Oren Meiron
Abstract: The present invention generally relates to the transdermal delivery of various compounds. In some aspects, transdermal delivery may be facilitated by the use of a hostile biophysical environment. One set of embodiments provides a composition for topical delivery comprising a phosphodiesterase type 5 inhibitor and/or a salt thereof, and optionally, a hostile biophysical environment and/or a nitric oxide donor. In some cases, the composition may be stabilized using a combination of a stabilization polymer (such as xanthan gum, KELTROL® BT and/or KELTROL® RD), propylene glycol, and a polysorbate surfactant such as Polysorbate 20, which combination unexpectedly provides temperature stability to the composition, e.g., at elevated temperatures such as at least 40° C. (at least about 104° F.), as compared to compositions lacking one or more of these.
Abstract: The invention relates to a capsule consisting of a shell and a filling, which contains plant sterol ester and/or plant stanol ester and emulsifier. The capsule is suitable for lowering serum LDL cholesterol level.
Type:
Grant
Filed:
October 17, 2014
Date of Patent:
June 2, 2020
Assignee:
RAISIO NUTRITION LTD
Inventors:
Päivi Kuusisto, Ingmar Wester, Leena Koponen, Jari Ekblom, Jouni Niemela
Abstract: A delayed release coating comprising a mixture of a first material selected from starch; amylose; amylopectin; chitosan; chondroitin sulfate; cyclodextrin; dextran; pullulan; carrageenan; scleroglucan; chitin; curdulan and levan, and a second material which has a pH threshold at about pH 5 or above, is used to target release of a drug from a core to the intestine, particularly the colon.
Type:
Grant
Filed:
March 15, 2019
Date of Patent:
June 2, 2020
Assignee:
University College London
Inventors:
Abdul Waseh Basit, Valentine Chidi Ibekwe
Abstract: The present invention relates to a pharmaceutical composition comprising linagliptin or a pharmaceutically acceptable salt thereof as active ingredient, wherein the pharmaceutical composition does not comprise a binder and wherein the pharmaceutical composition is obtained by direct compression.
Abstract: Core-shell particles and methods of making and using thereof are described herein. The core is formed of or contains one or more hydrophobic materials or more hydrophobic materials. The shell is formed of or contains hyperbranched polyglycerol (HPG). The HPG coating can be modified to adjust the properties of the particles. Unmodified HPG coatings impart stealth properties to the particles which resist non-specific protein absorption and increase circulation in the blood. The hydroxyl groups on the HPG coating can be chemically modified to form functional groups that react with functional groups and adhere the particles to tissue, cells, or extracellular materials, such as proteins.
Type:
Grant
Filed:
September 19, 2016
Date of Patent:
May 26, 2020
Assignee:
Yale University
Inventors:
Yang Deng, Asiri Ediriwickrema, William M. Saltzman